AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 3 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Although hepatitis B vaccine is somewhat less effective in patients with chronic hepatitis C, interferon-(alpha) therapy appears to make little difference as to whether or not a patient will become protected against hepatitis B virus (HBV) infection after being vaccinated.
A 1-year follow-up study of 48 chronic hepatitis C patients who received vaccinations against HBV was recently completed by researchers at the Medical Academy of Bialystok in Poland. The patients received a standard vaccine on routine vaccination schedules, with a fourth of the patients also receiving interferon-(alpha) therapy during the vaccination period.
"The overall seroprotection at month 7 was 72.9% in hepatitis C patients, compared with 90.9% in the controls," reported S. Chlabicz and colleagues.
By a year and a half after the first vaccine was administered, only a little more than a third of the chronic hepatitis C patients had developed titers high enough to be deemed protective against HBV, whereas all but 10% of a control group had (Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: The effect of interferon-(alpha) ...